menu-hamburger-svgrepo-com

ADAURA Phase III trial finds 51% reduction of lung cancer death after osimertinib

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

The results showed that Tagrisso reduced the risk of death by 51% compared to placebo in both the primary analysis and overall trial populations. The study also demonstrated a statistically significant and clinically meaningful improvement in overall survival compared to placebo in the adjuvant treatment setting.

Susan Galbraith, Executive Vice President of Oncology Research and Development at AstraZeneca, highlighted the significance of these findings, stating that Tagrisso's ability to halve the risk of death establishes it as a pivotal treatment for EGFR-mutated lung cancer. Galbraith emphasized the importance of early lung cancer diagnosis, testing for EGFR mutations, and treating all patients with an EGFR mutation with Tagrisso.

In addition to the adjuvant setting, Tagrisso is also being investigated in Phase III trials in the neoadjuvant resectable setting (NeoADAURA), the Stage IA2-IA3 adjuvant resectable setting (ADAURA2), and the Stage III locally advanced unresectable setting (LAURA). These studies aim to further explore the potential of Tagrisso in different stages and contexts of lung cancer treatment.

 

CLICK HERE TO READ THE ORIGINAL STUDY

Suggested Articles

Suggested Clinical & CPD content

CPD: 1pt
CPD: 1pt

Related articles

Welcome to Medical Academic​

Get the most out of Medical Academic by telling us your occupation. This helps us create more great content for you and the community.

idea

1000’s of Clinical and CPD content compiled by Key Opinion Leaders and our expert medical editors.

connection

Access to medical webinars and events

Group 193

Access medical journals from industry leaders and expert medical editorials.

Congratulations! Your account was successfully created.

Please check your email for an activation mail. Click the activation link to activate your account

Stay up to date

Search for anything across CPD, webinars and journals
idea

1000’s of Clinical and CPD content compiled by Key Opinion Leaders and our expert medical editors.

connection

Access to medical webinars and events

Group 193

Access medical journals from industry leaders and expert medical editorials.

Congratulations! You have successfully booked your seat.

All webinar details will be emailed to your email address.

Did you know, you can book future webinars with a single click if you register an account with Medical Academic.

Congratulations! Your account was successfully created.

Your webinar seat has been booked and all webinar details will be emailed to your registered email address

Why not register for Medical Academic while booking your seat for this webinar?

Future Medical Academic webinars can be booked with a single click, all with a Medical Academic account… and it’s FREE.

Book webinar & create your account

* (Required)

idea

1000’s of Clinical and CPD content compiled by Key Opinion Leaders and our expert medical editors.

connection

Access to medical webinars and events

Group 193

Access medical journals from industry leaders and expert medical editorials.

Congratulations! Your account was successfully created.

Thank you for registering. You can now log in to your account.

Create your account

* (Required)

Login with One Time Pin (OTP)

Enter your registered email address to receive an OTP

A verification code will be sent to your email address. Please ensure that admin@medicalacademic.co.za is on your safe sender list.

We've sent your OTP